shr1459
Small moleculeexperimental
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 6, 2018 (NCT03664297)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05560360 | Phase 1 | Nov 4, 2022 | Hengrui Therapeutics, Inc. |
| NCT05095337 | Phase 1 | Jan 31, 2022 | Hengrui Therapeutics, Inc. |
| NCT05136456 | Phase 2 | Nov 5, 2021 | Reistone Biopharma Company Limited |
| NCT04948788 | Phase 2 | Oct 31, 2021 | Hengrui Therapeutics, Inc. |
| NCT04670770 | Phase 2 | Dec 31, 2020 | Reistone Biopharma Company Limited |
| NCT04649723 | Phase 1 | Nov 24, 2020 | Hengrui Therapeutics, Inc. |
| NCT04455100 | Phase 1 | Jul 31, 2020 | Hengrui Therapeutics, Inc. |
| NCT04395053 | Phase 1 | May 31, 2020 | Hengrui Therapeutics, Inc. |
| NCT04291846 | Phase 1 | Mar 31, 2020 | Hengrui Therapeutics, Inc., Nanjing University |
| NCT03668509 | Phase 1 | Sep 1, 2018 | Hengrui Therapeutics, Inc. |
| NCT03664297 | Phase 1 | Feb 6, 2018 | Chinese Academy of Medical Sciences, Hengrui Therapeutics, Inc. |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 9 | 9 | 2 | 2018 |
| Reistone Biopharma Company Limited | For profit | 2 | 2 | 1 | 2020 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Nanjing University | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1